• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The Role of Mitochondrial Genes in Neurodegenerative Disorders
Curr Neuropharmacol. 2021 Sep 8. doi: 10.2174/1570159X19666210908163839. Online ahead of print.ABSTRACTMitochondrial disorders are clinically heterogeneous, resulting from nuclear gene and mitochondrial mutations that disturb the mitochondrial functions and dynamics. There is a lack of evidence linking mtDNA mutations to neurodegenerative disorders, mainly due to the absence of noticeable neuropathological lesions in postmortem samples. This review describes various gene mutations in Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, and Stroke. These abnormalities, including PINK1...
Source: Current Neuropharmacology - September 10, 2021 Category: Drugs & Pharmacology Authors: Rajesh Kumar Seetha Harilal Della Grace Thomas Parambi S K Kanthlal Md Atiar Rahman Athanasios Alexiou Gaber El-Saber Batiha Bijo Mathew Source Type: research

Neuroprotective Potential of Caffeic Acid Phenethyl Ester (CAPE) in CNS Disorders: Mechanistic and Therapeutic Insights
Curr Neuropharmacol. 2021 Jun 8. doi: 10.2174/1570159X19666210608165509. Online ahead of print.ABSTRACTNeurological disorders like Alzheimer's disease (AD), Parkinson's disease (PD), stroke, amyotrophic lateral sclerosis, Huntington's disease (HD), epilepsy, traumatic brain injury (TBI), depression and anxiety are responsible for thousands of deaths worldwide every year. With the increase in life expectancy, there has been a rise in the prevalence of these disorders. Age is one of the major risk factors for these neurological disorders and with the aged population is set to rise to 1.25 billion by 2050. There is a growing ...
Source: Current Neuropharmacology - June 9, 2021 Category: Drugs & Pharmacology Authors: Namrata Pramod Kulkarni Bhupesh Vaidya Acharan Narula Shyam Sunder Sharma Source Type: research

Poloxamer 188 (P188), A Potential Polymeric Protective Agent for Central Nervous System Disorders: A Systematic Review
Curr Neuropharmacol. 2021 May 28. doi: 10.2174/1570159X19666210528155801. Online ahead of print.ABSTRACTPoloxamer 188 (P188) is an FDA-approved biocompatible block copolymer composed of repeating units of poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO). Due to its amphiphilic nature and high hydrophile-lipophile balance (HLB) value of 29, P188 is used as a stabilizer/emulsifier in many cosmetics and pharmaceuticals preparations. While the applications of P188 as an excipient are widely explored, the data on the pharmacological activity of P188 are scarce. Notably, the neuroprotective potential of P188 has gained...
Source: Current Neuropharmacology - June 2, 2021 Category: Drugs & Pharmacology Authors: Win Ning Chen Mohd Farooq Shaikh Saatheeyavaane Bhuvanendran Abhijit Date Mohammad Tahir Ansari Ammu Kutty Radhakrishnan Iekhsan Othman Source Type: research

Pages: 1  2